ARAV - Aravive Inc Stock Price, Fair Value and News

0.04USD Market Closed

Market Summary

USD0.04

Market Closed

ARAV Stock Price

View Fullscreen

ARAV RSI Chart

ARAV Valuation

Market Cap

2.9M

Price/Earnings (Trailing)

-0.07

Price/Sales (Trailing)

0.42

EV/EBITDA

0.04

Price/Free Cashflow

-0.05

ARAV Price/Sales (Trailing)

ARAV Profitability

EBT Margin

-807.23%

Return on Equity

-2.3K%

Return on Assets

-305.36%

Free Cashflow Yield

-2.0K%

ARAV Fundamentals

ARAV Revenue

Revenue (TTM)

7.0M

ARAV Earnings

Earnings (TTM)

-39.8M

Breaking Down ARAV Revenue

Last 30 days

-66.7%

Last 90 days

-71.4%

Trailing 12 Months

-97.6%

How does ARAV drawdown profile look like?

ARAV Financial Health

Current Ratio

0.98

ARAV Investor Care

Shares Dilution (1Y)

22.96%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	9.5M	9.2M	7.0M	0
2022	8.3M	6.1M	8.6M	9.1M
2021	6.1M	6.6M	7.0M	7.4M
2020	0	0	0	5.7M
2019	25.9M	18.9M	11.8M	4.8M
2018	0	0	0	33.0M
2017	0	0	0	40.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Aravive Inc

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

CEO	Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D.
WEBSITE	https://aravive.com
INDUSTRY	Biotechnology
EMPLOYEES	23

Aravive Inc Frequently Asked Questions

What is the ticker symbol for Aravive Inc? What does ARAV stand for in stocks?

ARAV is the stock ticker symbol of Aravive Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aravive Inc (ARAV)?

As of Wed Feb 07 2024, market cap of Aravive Inc is 2.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARAV stock?

You can check ARAV's fair value in chart for subscribers.

Is Aravive Inc a good stock to buy?

The fair value guage provides a quick view whether ARAV is over valued or under valued. Whether Aravive Inc is cheap or expensive depends on the assumptions which impact Aravive Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARAV.

What is Aravive Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 07 2024, ARAV's PE ratio (Price to Earnings) is -0.07 and Price to Sales (PS) ratio is 0.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARAV PE ratio will change depending on the future growth rate expectations of investors.